arXivDaily arXiv每日学术速递 周一至周五更新
arXiv 2101.09050cs.AIq-bio.BM
收藏

Chemistry42:一个基于AI的从头分子设计平台

Chemistry42: An AI-based platform for de novo molecular design

Insilico Medicine Hong Kong Ltd.(英矽智能香港有限公司)

Yan A. Ivanenkov, Alex Zhebrak, Dmitry Bezrukov, Bogdan Zagribelnyy, Vladimir Aladinskiy, Daniil Polykovskiy, Eugene Lane, Petrina Kamya, Alexander Aliper, Alex Zhavoronkov

AI总结:

Chemistry42是一个基于AI的从头小分子设计平台,融合AI与计算及药物化学方法,能生成经实验验证具预定义属性的新分子,是Insilico Medicine药物发现套件的核心组件。

摘要:

Chemistry42是一个用于从头小分子设计的软件平台,它将人工智能(AI)技术与计算化学及药物化学方法相集成。Chemistry42的独特之处在于能够生成具有预定义属性的新型分子结构,并通过体外和体内研究进行验证。Chemistry42是Insilico Medicine Pharma.ai药物发现套件的核心组件,该套件还包括靶点发现和多组学数据分析(PandaOmics)以及临床试验结果预测(InClinico)。

英文摘要:

Chemistry42 is a software platform for de novo small molecule design that integrates Artificial Intelligence (AI) techniques with computational and medicinal chemistry methods. Chemistry42 is unique in its ability to generate novel molecular structures with predefined properties validated through in vitro and in vivo studies. Chemistry42 is a core component of Insilico Medicine Pharma.ai drug discovery suite that also includes target discovery and multi-omics data analysis (PandaOmics) and clinical trial outcomes predictions (InClinico).

机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。

↑